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Abstract
Aligning innovation processes in healthcare with health system demands is a societal objective, not always 
achieved. In line with earlier contributions, Lehoux et al outline priorities for research, public communication, 
and policy action to achieve this objective. We endorse setting these priorities, while also highlighting a 
‘commitment gap’ in collectively addressing system-level challenges. To acknowledge that stakeholders engaged 
in dialogue with one another are addressing the commitment gap is not a small step but a giant leap towards 
realising a socially responsible innovation agenda. Translating system-level demand signals into innovation 
opportunities is, therefore, the task-cum-art of all stakeholders, one that often prompts them to innovate how 
they deal with innovations. 
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Advances in healthcare technology over the last 50 years have contributed to improving life expectancy, reducing patients morbidities, and 
offering professionals opportunities to improve the quality 
and efficiency of healthcare.1 The influx of innovations 
into publicly-funded healthcare systems continues and 
horizons are constantly being pushed. ‘Innovation’ carries 
a strong connotation of ‘novelty’ and recency.2 Although 
this conceptualisation has dominated present-day thinking 
about innovation in healthcare, it would be naive to maintain 
that changing to whatever is ‘new’ is inherently good. True 
innovation must be a change for the better. 
Is “New” Invariably “Better”?
While an innovation’s recency seems straightforward, its 
betterment is often not. 
First, diverse stakeholders involved in the development, 
adoption, spread, and regulation of new technology hold 
diverse visions on an innovation’s value, ranging from 
achieving market competition and entrepreneurship, to 
promoting population health, equitable access, and universal 
coverage.3-5 These visions often collide in theory and practice. 
For instance, a policy aimed at ‘pushing’ entrepreneurial start-
ups to create business value, like in the case of medical and 
wellness apps, might result in innovations that are suboptimal 
in creating aggregate social value.3,6,7
Second, many innovative surgical devices, treatment 
strategies, imaging equipment, apps, etc are adopted and used 
in decentralised arrangements while their clinical benefits 
and value for the costs they incur to the health system remain 
largely understudied.8-10 Existing regulations for market 
entry and acquisition practices of in-hospital and digital 
technologies do not often require substantial evidence of 
(cost)effectiveness up-front. 
Third, implementation is ‘open-ended’ as in the case of 
predictive AI algorithms, hybrid operating rooms, gene 
editing, etc. The route from an innovation’s ‘black boxed’ 
promises to actual value is convoluted and conditional to, 
amongst others, an appropriate infrastructure, training, users’ 
experience, safety and privacy protocols, liability, business 
model, and maintenance.2,3 
Fourth, dissemination of new diagnostic and therapeutic 
technologies can contribute, in a self-perpetuating fashion, to 
unrealistic expectations, inflated patient demands, increased 
health anxiety, over-treatment, and medicalisation. Hence, 
ethical suitability in terms of how an innovation shapes the 
ideals of social service delivery, definitions of human disease, 
and patterns of resource allocation in healthcare are also often 
unclear and under-examined.11,12 
Fifth, medical innovations raise concerns about the 
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affordability of both well-developed  and developing healthcare 
systems. They drive expenditure growth, being responsible 
on average for half the annual increase in healthcare costs.13,14 
Spreading at an inelastic, high unit price (eg, surgical robots), 
growing use (CT/MRI scans), or expanding indications (heart 
implants) can explain expenditure growth.4,15 Moreover, new 
technologies may attract many resources within and beyond 
adopting organisations, thereby eliminating the provision of 
‘less lucrative’ services (eg, counselling).11,16 Concerns about 
affordability and access can jeopardise citizens’ support for 
maintaining a publicly-funded healthcare system, hence 
shaking the pillars of social solidarity. 
Just as healthcare innovations may be part of the ‘solution’ 
by promising some benefits, they may also be part of the 
‘problem’ by causing – sometimes far-reaching – consequences 
to the healthcare system, particularly if the investment is 
high, ethical issues are at stake, or the added value for patient 
is limited.2 An innovation does not automatically lead to 
betterment when its value to society at large is at stake. 
Begin With the End in Mind!
The article by Lehoux et al is an important contribution to 
dealing with the problem of medical technology, ie, achieving 
betterment from innovations.6 Drawing on the principles of 
responsible research and innovation, the article emphasises 
the issue of aligning healthcare innovations with public 
healthcare system objectives. 
The conceptual core of the article is almost self-evident: 
insofar as new technologies are provided within public 
healthcare systems, they need to contribute to population 
health, quality of care, access, and financial sustainability. 
However, Lehoux et al wonder why system-level challenges 
have so far not been adequately addressed. We find this 
much less surprising given the explanations the article itself 
provides. The bottom-line is this: ‘current incentives, practices 
of technology introduction, and regulation mechanisms are 
not well supporting or rewarding the public goods that health 
systems need.’6 
The article contributes to the theory and practice of 
responsible innovation in healthcare in the following respects: 
signalling obstacles, describing priorities, and recommending 
policy proposals. The obstacles include (i) a research gap 
partly because literature is scattered across different scientific 
disciplines, geographies, patient groups and services, (ii) a 
communication gap in articulating system-level priorities 
explicitly, and (iii) an action gap in setting societal challenges 
at the outset when developing innovation trajectories in 
healthcare. To this, we add (iv) an overarching commitment gap 
in collectively filling the above-mentioned gaps. The article 
attempts to fill the research gap by providing a comprehensive 
scoping review of system-level challenges in different health 
systems across the Human Development Index spectrum. 
Using the ‘dynamic health system’ analytical framework, 
the authors explicitly articulate the ‘demand’ (priorities) 
for innovation from a public health system perspective. In 
addition, a range of policy initiatives at different stages of the 
innovation process are recommended to address the action 
gap.6 
A “Giant Leap” Forward
We endorse the priorities for research, public communication, 
and policy action provided by Lehoux et al and believe these 
are essential building blocks for making an innovation agenda. 
However, commitment matters. The authors emphasise that 
‘translating system-level demand signals into innovation 
opportunities’ is the task of policy-makers. We believe this is 
the task-cum-art[1] of all stakeholders including technology 
developers, users/patients, assessors/payers, and policy-
makers. Once health system challenges are placed centre 
stage throughout the innovation process, a shared agenda 
can be formed in accordance with responsible innovation 
in healthcare. Stakeholders can then engage in deliberation 
as to how to align on and co‑create social value from 
innovations.3 Co-creating value may not prove easy, given 
the divergent interests and dispersed tasks; acknowledging it 
as a responsibility of us all, however, is key to addressing the 
commitment gap.3 This is not a small step but a giant leap 
towards realising a socially responsible innovation agenda.
Rather than regarding health system priorities as ‘hurdles’ 
to innovation or ‘valleys of death,’ investors and technology 
developers can embrace them. A distinctive business logic 
involves: catering for system-level demands (eg, access) 
to develop readily-scalable solutions rather than niche 
marketing. This means prioritising service innovation (eg, 
digital patient-referral or waiting-list solutions) and making 
intangibles (eg, patents, algorithms, return on investment 
models) responsive to public health priority problems; in 
other words shifting from ‘fancy’ to ‘frugal’ and ‘less sexy’ 
innovations.3,6,17,18 As a result, social entrepreneurial strategies 
can be devised that enhance rather than limit commercial 
opportunities. Along with a duty at the outset to respond 
to system-level challenges comes the advantage of getting 
the innovation publicly-procured and scaled up within a 
healthcare system. 
Setting system-level challenges at the outset also has 
important capacity-building implications for health 
technology assessment (HTA).19 It helps enrich the role, 
methodology, and future direction of HTA as the knowledge 
tool situated at the intersection of research and innovation 
policy. This opens up new foci in HTA, characterised by 
attentiveness to real-world practices, involvement in the 
early stages of innovations, and incorporation of insights 
from ‘constructive technology assessment’ and ‘value-based 
healthcare.’3,20 This is in accordance with the need for an 
evaluative knowledge within the innovation ecosystem that 
is adaptive (no one-size-fits-all), reflexive, and anticipatory.6,21
Public communication on health system objectives enhances 
public awareness of these objectives and strengthens a critical 
scrutiny of (supply-induced) demands for an innovation in 
the face of seductive advertisements.22 It is the appreciation of 
health system challenges that can prompt users/adopters of an 
innovation to become more self-reflexive regarding their own 
expectations of innovation and system-level consequences 
of their decisions. In addition, cultural change agents and 
pedagogic communication experts can, similar to health 
promotion endeavours, contribute to promoting the mind-
set of appropriate use of innovations in clinical practice and 
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medical curricula. 
Finally, a “translation” of system-level demands into 
innovation priorities by policy-makers renders a complex 
mix of governance and social-marketing initiatives.6,23 This 
includes the following: streamlining existing local policies 
by partnering the organisations involved in innovation 
policy with those of public health policy, facilitating 
interaction between stakeholders on the innovation’s push-
side (entrepreneurship) and pull-side (public health), 
upscaling innovations within conditional access schemes 
while also harnessing big-data potentials for an outcome-
based financing, valorising and financially rewarding social 
value-driven intangibles, and prioritising public debate on the 
societal desirability and appropriate use of new treatments. 
Policy-makers and public authorities will accordingly need 
to adjust their modus operandi from performing as ad hoc, 
reactive rule-setters to all-round, proactive moderators of 
innovation practices towards achieving socially desirable 
ends.3 To do so, policy-makers may need to innovate how 
they communicate and regulate innovations.
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Endnote
[1] The task-cum-art of translating health system demands into innovation 
opportunities is not a mere technical task, but one requiring compassion, 
commitment, courage, and creativity. 
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